| Schedule of Segment Reporting Financial Information |
The following table presents selected financial information with respect to the Company’s single operating segment for the three and six months ended March 31, 2026 and 2025 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, |
|
|
Six Months Ended March 31, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue |
|
|
|
|
|
|
|
|
|
|
|
|
Royalty revenue |
|
$ |
17,159 |
|
|
$ |
14,926 |
|
|
$ |
35,774 |
|
|
$ |
31,885 |
|
Total revenue |
|
|
17,159 |
|
|
|
14,926 |
|
|
|
35,774 |
|
|
|
31,885 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
RSV |
|
|
4,933 |
|
|
|
17,794 |
|
|
|
9,854 |
|
|
|
36,207 |
|
Total virology |
|
|
4,933 |
|
|
|
17,794 |
|
|
|
9,854 |
|
|
|
36,207 |
|
KIT |
|
|
3,726 |
|
|
|
3,588 |
|
|
|
8,571 |
|
|
|
7,845 |
|
STAT6 |
|
|
6,394 |
|
|
|
3,705 |
|
|
|
13,495 |
|
|
|
5,993 |
|
MRGPRX2 |
|
|
2,612 |
|
|
|
2,471 |
|
|
|
4,869 |
|
|
|
4,548 |
|
Total immunology |
|
|
12,732 |
|
|
|
9,764 |
|
|
|
26,935 |
|
|
|
18,386 |
|
Early discovery |
|
|
1,572 |
|
|
|
153 |
|
|
|
3,151 |
|
|
|
512 |
|
Other pipeline programs |
|
|
206 |
|
|
|
354 |
|
|
|
362 |
|
|
|
616 |
|
Total other programs |
|
|
1,778 |
|
|
|
507 |
|
|
|
3,513 |
|
|
|
1,128 |
|
General and administrative |
|
|
9,568 |
|
|
|
11,388 |
|
|
|
18,577 |
|
|
|
24,234 |
|
Total operating expenses |
|
|
29,011 |
|
|
|
39,453 |
|
|
|
58,879 |
|
|
|
79,955 |
|
Loss from operations |
|
|
(11,852 |
) |
|
|
(24,527 |
) |
|
|
(23,105 |
) |
|
|
(48,070 |
) |
Other income (expense): |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
(3,316 |
) |
|
|
(1,714 |
) |
|
|
(6,399 |
) |
|
|
(3,676 |
) |
Interest and investment income, net |
|
|
2,084 |
|
|
|
2,292 |
|
|
|
4,506 |
|
|
|
5,091 |
|
Total other (expense) income, net |
|
|
(1,232 |
) |
|
|
578 |
|
|
|
(1,893 |
) |
|
|
1,415 |
|
Loss before income taxes |
|
|
(13,084 |
) |
|
|
(23,949 |
) |
|
|
(24,998 |
) |
|
|
(46,655 |
) |
Income tax (expense) benefit |
|
|
(7 |
) |
|
|
1,305 |
|
|
|
(31 |
) |
|
|
1,721 |
|
Net loss |
|
$ |
(13,091 |
) |
|
$ |
(22,644 |
) |
|
$ |
(25,029 |
) |
|
$ |
(44,934 |
) |
|